OTTAWA, ON – Scientists from Blood Systems Research Institute in San Francisco, California, and Canadian Blood Services’ Centre for Innovation lab in Edmonton, Alberta, report for the first time that specific red blood cell manufacturing methods may be less damaging to cells than others. This finding could help reduce adverse reactions in transfusion recipients and may impact the future of how blood is collected in North America and around the world.
Spurred by three decades of momentum and fresh funding, scientists mount a major effort to finally defeat AIDS.
“Under Larry’s direction, BSRI-Denver will be an important participant and contributor in the development and evaluation of new methods, devices and biological products in transfusion medicine,” said Michael Busch, M.D., Ph.D., Blood Systems Senior Vice President for Research and Scientific Programs and BSRI Co-Director. “BSRI has a strong reputation for innovative scientific research and policy development, built over more than half a century. The Denver initiative, with Larry’s leadership and Bonfils’ exceptional facilities, brings BSRI squarely into the development arena of R&D with the practical application of scientific knowledge to make a real difference in the lives of patients who receive transfusions.”
Funded by grants from the National Institutes of Health, scientists at Blood Systems Research Institute (BSRI) in San Francisco and the Washington University School of Medicine in St. Louis have found that neutralizing antibodies that engage epitopes including residue E2-W64 are highly potent at inhibiting the virus in mice, due to the importance of E2-W64 in pathogenicity. Furthermore, these antibodies prevent CHIKV from both entering and exiting cells, whereas prior studies of neutralizing antibodies to CHIKV and multiple other classes of viruses have focused on the capacity to block viruses from entering a cell.
NEW YORK, November 30, 2015 – amfAR, The Foundation for AIDS Research, today announced the establishment of the amfAR Institute for HIV Cure Research, an innovative collaborative enterprise based at the University of California, San Francisco (UCSF). As the cornerstone of amfAR’s $100 million cure research investment strategy, the aim of the Institute will be to develop the scientific basis of a cure for HIV by the end of 2020.
BSRI's annual scientific retreat took place on September 13 at San Francisco's historic Fort Mason Center. Associate Investigator Graham Simmons organized this virus-focused event which included presentations by BSRI investigators Eric Delwart and Satish Pillai. Joining our investigators were three invited speakers, William Robinson, MD, PhD (Stanford University), Sean Amberg, PhD (SIGA Technologies) and William Switzer, MPH (CDC Division of HIV/AIDS Prevention).